Scientists zoom in on AIDS virus hideout

March 15, 2017
HIV-1 Virus. Credit: J Roberto Trujillo/Wikipedia

French scientists said Wednesday they had found a way to pinpoint elusive white blood cells which provide a hideout for the AIDS virus in people taking anti-HIV drugs.

Being able to spot, and one day neutralise, these "reservoir" cells has long been a holy grail in the quest to wipe out AIDS and the (HIV) that causes it.

The discovery "paves the way to a better fundamental understanding of viral reservoirs," said France's CNRS research institute, which took part in the study published in Nature.

"In the longer term, it should lead to therapeutic strategies aiming to eliminate the latent virus," it added in a statement.

There is no cure for HIV, and infected people have to take virus-suppressing drugs for life.

This is because a small number of , in a category of cell called CD4 T lymphocytes, provide a haven for the virus, enabling it to re-emerge and spread if treatment is stopped— even after decades.

In tests using the blood of HIV patients, the researchers managed to spot a protein, dubbed CD32a, on the surface of virus-infected reservoir cells.

It was absent from .

Such a "marker" has proved very difficult to find, explained AIDS researcher Douglas Richman from the University of California San Diego, who did not take part in the study.

A person infected with HIV has about 200 billion CD4 T cells, of which only one in a million act as virus reservoirs.

Two percent of the body's CD4 T cells (some four billion) are found in the approximately five litres of blood in an adult human, said Richman.

This means that a 100-millilitre blood sample would contain about 80 million CD4 T cells, of which around 80 would be virus reservoirs.

Whether CD32a plays an active part in enabling the to hole up in CD4 cells is a big question.

If so, it could throw open a tempting target for drugs to block the stealthy process.

While describing the study as "potentially seminal", Richman cautioned that CD32a was a marker found in only about half of CD4 T reservoir cells.

To eradicate latent HIV would require the targeting of a much larger proportion.

It also remains to be seen whether CD32a is as good a marker for non-blood CD4 T in the lymph nodes, bone marrow, gut and other tissues which could be reservoirs, he added.

Explore further: Immune-enhancing treatment may destabilize HIV reservoirs

More information: Benjamin Descours et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses, Nature (2017). DOI: 10.1038/nature21710

Related Stories

Immune-enhancing treatment may destabilize HIV reservoirs

July 21, 2016
Although antiretroviral therapy (ART) can reduce the amount of HIV in the blood to an undetectable level in most chronically infected people, it cannot eliminate reservoirs of HIV that persist in latently infected immune ...

Study observes potential breakthrough in treatment of HIV

June 17, 2016
A new study conducted by researchers at the San Francisco VA Medical Center (SFVAMC) observes that pharmacological enhancement of the immune systems of HIV patients could help eliminate infected cells, providing an important ...

HIV 'safe houses' identified

July 14, 2016
Researchers from the University of Montreal Hospital Research Center (CRCHUM) have identified cells that provide "safe houses" for the human immunodeficiency virus (HIV) during antiretroviral therapy (ART).

Targeting dormant HIV

September 19, 2016
Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS ...

Targeting HIV 'reservoir' could be first step to understanding how to cure the disease

December 1, 2015
A new clinical trial will test whether it is possible to destroy hidden reservoirs of HIV virus that are a key obstacle to curing the disease.

Identification of drug combinations that reverse HIV-1 latency

March 30, 2015
There are almost 40 million people throughout the world living with HIV-1/AIDs. While current antiretroviral therapies are able to reduce the amount of virus in the blood, HIV remains present in a latent state within T cells. ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.